---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-21-001525"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T14:02:42.665359+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics appoints Dr. Urte Gayko to Board of Directors

## Summary
- Dr. Urte Gayko appointed to Summit's Board effective Nov 3, 2021; will serve on Nominating and Corporate Governance Committee.
- Gayko is SVP of Drug Development & Regulatory Affairs at Nektar Therapeutics; previously Global Head of Regulatory at Pharmacyclics.
- Over 20 years experience in regulatory and clinical development across Amgen, AbbVie, and biotech; PhD in molecular/cellular biology from Harvard.
- She received an option grant under Summit's non-employee director compensation policy; also standard indemnification agreement.
- Board determined Gayko qualifies as independent director under Nasdaq listing rules.

## SEC filing metadata
- accession: 0001193805-21-001525
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/0001193805-21-001525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/e621052_8k-summit.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-21-001525
- JSON: https://secwatch.observer/filing/0001193805-21-001525.json
- Plain text: https://secwatch.observer/filing/0001193805-21-001525.txt

## Key facts
- Executive change
  Urte Gayko was elected as director at Summit Therapeutics Inc..
  - Action: elected
  - Role: director
  source text: Effective on November 3, 2021, the board of directors (the “Board”) of Summit Therapeutics Inc. (the “Company”) unanimously approved (i) the election of Urte Gayko as a director of the Company, to occupy a newly created seat on the Board and (ii) the appointment of Dr. Gayko to serve on the Nominating and Corporate Governance Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/0001193805-21-001525-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.